FDA gives Rituxan priority review

Submitted by mike Wed 10/26/2005

Share on Tumblr

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Genentech Inc. and Biogen Idec Inc. said on Tuesday their cancer drug Rituxan will get a speedy review from U.S. regulators for the treatment of aggressive, but previously untreated non-Hodgkin's lymphoma.

Genentech and Biogen Idec already sell Rituxan as a treatment for non-Hodgkin's lymphoma. The companies are seeking approval for the drug as a first-line therapy for patients with intermediate grade or aggressive, CD20-positive, B-cell, non-Hodgkin's lymphoma (NHL), in combination with chemotherapy.

The drug has been granted priority review status, giving the U.S. Food and Drug Administration up to six months to take action on the application, which was submitted on Aug. 12.

Currently, more than 360,000 people in the United States live with NHL. About half have the aggressive form. (Reuters)

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Support Groups

SupportGroups.com

For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Cancer Support Groups

Find a Treatment Facility Near You

Click on a state below to find Lymphoma treatment options that could be right for you.

Select a State Below

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.